4//SEC Filing
Sepp-Lorenzino Laura 4
Accession 0001209191-23-002433
CIK 0001652130other
Filed
Jan 5, 7:00 PM ET
Accepted
Jan 6, 5:39 PM ET
Size
9.1 KB
Accession
0001209191-23-002433
Insider Transaction Report
Form 4
Sepp-Lorenzino Laura
EVP, Chief Scientific Officer
Transactions
- Sale
Common Stock
2023-01-05$39.10/sh−689$26,940→ 17,629 total - Sale
Common Stock
2023-01-04$37.21/sh−2,508$93,323→ 19,959 total - Sale
Common Stock
2023-01-05$38.22/sh−1,641$62,719→ 18,318 total
Footnotes (4)
- [F1]Shares sold in sell-to-cover transaction in order to satisfy withholding taxes to be paid upon the vesting of RSUs on January 1, 2023.
- [F2]The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.80 to $38.78, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.30, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on January 5, 2023 at each separate price.
Documents
Issuer
Intellia Therapeutics, Inc.
CIK 0001652130
Entity typeother
Related Parties
1- filerCIK 0001777421
Filing Metadata
- Form type
- 4
- Filed
- Jan 5, 7:00 PM ET
- Accepted
- Jan 6, 5:39 PM ET
- Size
- 9.1 KB